Selectively replicating viral vectors

Rotavirus NSP4 protein as a viral biotoxin selectively promotes cytotoxicity

Abstract Background and Aims: The number of new cancer cases with considerable mortality is increasing worldwide. Since the inability of current therapies in treatment of patients and prevention the progress of tumors with fewer side effects, implementation of new methods is needed. Gene therapy has widespread systemic cytotoxic effects against tumor cells. Rotavirus NSP4 has been shown to...

Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses

Tumour-specific replicating (oncolytic) viruses are novel anticancer agents, currently under intense investigation in preclinical studies and phase I-III clinical trials. Until recently, most studies have focused on the direct antitumour properties of these viruses. There is now an increasing body of evidence indicating that host immune responses may be critical to the efficacy of oncolytic vir...

Conditionally replicating herpes vectors for cancer therapy.

P164: Adeno-Associated Viral Vectors in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (BMD) is an inherited X-link disease. The incidence of this muscle-wasting disease is 1:5000 male live births. Mutation in the gene coding for dystrophin is the main cause of BMD. Most cases of this disease succumb to respiratory and cardiac failure in 3rd to 4th decades. The slow progression of BMD and recent achievement of gene therapies make it as an appropriate c...

Engineering influenza viral vectors

The influenza virus is a respiratory pathogen with a negative-sense, segmented RNA genome. Construction of recombinant influenza viruses in the laboratory was reported starting in the 1980s. Within a short period of time, pioneer researchers had devised methods that made it possible to construct influenza viral vectors from cDNA plasmid systems. Herein, we discuss the evolution of influenza vir...